- Only company in the world with patent for the oral or ingestible delivery of all non-psychoactive cannabinoids
- Uplisted to OTCQX® Best Market
- Licensing model generates profit margins in excess of 90 percent
A new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes, according to the New York Times (http://cnw.fm/Eay21). While warning against the risk of nicotine addiction posed by vaping, the report claimed “that the devices are safer than traditional smoking products and may help smokers quit, citing conclusive proof that switching can reduce smokers’ exposure to deadly tar, dangerous chemicals and other carcinogens.” Although nicotine is most often cited in indictments against smoking, it is not a carcinogen and appears to have little effect on cardiovascular health. Indeed, its use has been credited with health benefits (http://cnw.fm/Bay7u), with its bad rap being attributed to its method of delivery, such as inhaling tobacco smoke. This report highlights the importance of drug delivery methodologies like those developed by Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP). The company, recently uplisted to the OTCQX® Best Market, has developed technology that allows nicotine to be absorbed without smoking.
Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to the 60-90 minutes required for current methods, and is already in use in a number of consumer products. The technology is already attracting the attention of Big Pharma, and Lexaria is in negotiations with major pharmaceutical companies to license its technology. The smallest deal with any one of these could increase revenues by over $1 million, and the largest could increase revenues by much, much more, as noted by CEO Chris Bunka in a recent interview (http://cnw.fm/Qst5C). Lexaria’s licensing model will generate revenues at very little cost, leaving upward of 90 percent of revenues as profit.
Presently, Lexaria is the only company in the world that has been awarded a patent for the improved (oral or ingestible, including pills) delivery of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs. Rather than being a competitor to clinical stage biotech companies, Lexaria plans to be an enabler.
Earlier this month, OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, announced that Lexaria Bioscience Corp. had qualified to trade on the OTCQX® Best Market (http://cnw.fm/Z81uj). Lexaria upgraded to OTCQX from the OTCQB® Venture Market. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and have a professional third-party sponsor introduction. Penny stocks, shells and companies in bankruptcy cannot qualify for OTCQX. Per the OTC Markets website, the companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications.
For more information, visit the company’s website at www.LexariaEnergy.com
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com